Literature DB >> 27780631

Meningococcal disease in the Asia-Pacific region: Findings and recommendations from the Global Meningococcal Initiative.

Ray Borrow1, Jin-Soo Lee2, Julio A Vázquez3, Godwin Enwere4, Muhamed-Kheir Taha5, Hajime Kamiya6, Hwang Min Kim7, Dae Sun Jo8.   

Abstract

The Global Meningococcal Initiative (GMI) is a global expert group that includes scientists, clinicians, and public health officials with a wide range of specialties. The purpose of the Initiative is to promote the global prevention of meningococcal disease (MD) through education, research, and cooperation. The first Asia-Pacific regional meeting was held in November 2014. The GMI reviewed the epidemiology of MD, surveillance, and prevention strategies, and outbreak control practices from participating countries in the Asia-Pacific region.Although, in general, MD is underreported in this region, serogroup A disease is most prominent in low-income countries such as India and the Philippines, while Taiwan, Japan, and Korea reported disease from serogroups C, W, and Y. China has a mixed epidemiology of serogroups A, B, C, and W. Perspectives from countries outside of the region were also provided to provide insight into lessons learnt. Based on the available data and meeting discussions, a number of challenges and data gaps were identified and, as a consequence, several recommendations were formulated: strengthen surveillance; improve diagnosis, typing and case reporting; standardize case definitions; develop guidelines for outbreak management; and promote awareness of MD among healthcare professionals, public health officials, and the general public.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Asia-Pacific; Epidemiology; Global Meningococcal Initiative; Meningococcal disease; Recommendations; Surveillance

Mesh:

Year:  2016        PMID: 27780631     DOI: 10.1016/j.vaccine.2016.10.022

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12-23 months in China.

Authors:  Jialei Hu; Hongguang Li; Kai Chu; Qi Liang; Jingxin Li; Li Luo; Yuemei Hu; Fanyue Meng; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2019-07-26       Impact factor: 3.452

Review 2.  Challenges and opportunities for meningococcal vaccination in the developing world.

Authors:  Rouba Shaker; Danielle Fayad; Ghassan Dbaibo
Journal:  Hum Vaccin Immunother       Date:  2018-02-23       Impact factor: 3.452

3.  Results from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 years.

Authors:  Byung Wook Yoo; Hye Lim Jung; Yoon Seob Byeon; Dong Ki Han; Nak Yeong Jeong; Carlo Curina; Luca Moraschini; Sung Jin Kim; Chiranjiwi Bhusal; Michele Pellegrini; Yan Miao
Journal:  Hum Vaccin Immunother       Date:  2019-10-25       Impact factor: 3.452

4.  The need for school administrative policies to manage meningitis amongst students in Nigeria: a viewpoint.

Authors:  Uju A Nwobi; Chiedu Eseadi; Charity C Okide; Kingsley Asogu Ogbonnaya; Ruphina Nwachukwu; Liziana N Onuigbo; Angie I Oboegbulem; Okechukwu O Nwaubani; Uchenna C Ugwu; Nkiru C Ohia; Eucharia N Aye; Kennedy O Ololo; Justina Ifeoma Ofuebe; Bernedeth N Ezegbe
Journal:  J Int Med Res       Date:  2018-09-09       Impact factor: 1.671

5.  [Genotypes of Neisseria meningitidis isolates in patients with meningococcal meningitis in Paraguay, 1996-2015Genótipos de Neisseria meningitidis isolados de pacientes com doença meningocócica no Paraguai, 1996-2015].

Authors:  María Eugenia León; Aníbal Kawabata; Minako Nagai; Liliana Rojas; Gustavo Chamorro
Journal:  Rev Panam Salud Publica       Date:  2019-02-13

6.  Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults.

Authors:  Han Wool Kim; Soyoung Lee; Ji Hyen Lee; So Youn Woo; Kyung Hyo Kim
Journal:  J Korean Med Sci       Date:  2019-06-17       Impact factor: 2.153

7.  Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.

Authors:  Nan-Chang Chiu; Li-Min Huang; Arnold Willemsen; Chiranjiwi Bhusal; Ashwani Kumar Arora; Zenaida Reynoso Mojares; Daniela Toneatto
Journal:  Hum Vaccin Immunother       Date:  2018-02-15       Impact factor: 3.452

Review 8.  Progress toward the global control of Neisseria meningitidis: 21st century vaccines, current guidelines, and challenges for future vaccine development.

Authors:  A W Dretler; N G Rouphael; D S Stephens
Journal:  Hum Vaccin Immunother       Date:  2018-05-09       Impact factor: 3.452

Review 9.  Carriage of Neisseria Meningitidis in Low and Middle Income Countries of the Americas and Asia: A Review of the Literature.

Authors:  Lidia Serra; Jessica Presa; Hannah Christensen; Caroline Trotter
Journal:  Infect Dis Ther       Date:  2020-04-02

Review 10.  Recent Advances in the Synthesis of Glycoconjugates for Vaccine Development.

Authors:  Cinzia Colombo; Olimpia Pitirollo; Luigi Lay
Journal:  Molecules       Date:  2018-07-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.